analysts news from FierceBiotech
News
Lilly sees pipeline hope in MS drug
An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for Read more...
Novartis, MorphoSys ink $1B antibody deal
There's fresh evidence this morning that antibodies remain one of the hottest commodities in biotechnology. Novartis has extended its antibody development deal with Germany's MorphoSys, agreeing to Read more...
Organon experiences Schering's research 'religion'
The Star-Ledger sat down with Tom Koestler, the research chief for Schering-Plough, to review its progress developing new therapies and integrating the R&D section of Organon. Koestler and CEO Read more...
Investors fret over Lilly's pipeline, Prasugel data
Barron's concludes that Eli Lilly's anti-clotting drug Prasrugel will probably make it to the market, but recent safety data is likely to prevent it from becoming the kind of blockbuster the drug Read more...
Antisoma shares tank on bold new trial strategy
Shares of Antisoma took a dive this morning after researchers announced that they would pit ASA404 against Roche and Read more...
Doubters see big obstacles for Lilly's Prasrugel
The news that Eli Lilly's experimental anti-clotting drug Prasrugel was linked with a higher risk of fatal bleeding has converted a large group of analysts into disbelievers in the company's stock Read more...
SPOTLIGHT: Analyst: AZ "worst performer" in pharma
So, Dresdner Kleinwort, tell us how you really feel about AstraZeneca. The investment bank, which just started covering AstraZeneca's stock, minced no words in its first report. The company's in "Read more...
Novartis faces delay rolling out Galvus
Novartis is staring at some serious problems rolling out its diabetes drug Galvus. New data showing patients taking higher doses of the drug--100 mg--demonstrated more frequent enzyme elevation Read more...
SPOTLIGHT: FDA rejects Glaxo depression drug
The FDA has turned thumbs down on GlaxoSmithKline's gepirone ER for major depression. Glaxo had licensed the drug from Fabre-Kramer after Akzo Nobel had bowed out of an earlier partnership. Analysts Read more...
Safety questions cloud future of Takeda's TAK-475
One of Takeda's brightest drug prospects has run into a major stumbling block. The FDA is recommending the company halt clinical trials that are using higher doses of TAK-475 after seeing signs of Read more...
Get more analysts coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends